cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationship between <sup>18</sup>F-FDG PET metabolic parameters and MRI intravoxel incoherent motion (IVIM) histogram parameters and their correlations with clinicopathological features of cervical cancer: evidence from integrated PET/MRI.
|
30545566 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study describes the frequency and sites of distant metastatic disease at diagnosis in patients with cervical cancer as detected by positron emission tomography with <sup>18</sup>F-fluorodeoxyglucose (FDG-PET).
|
30739082 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influence of 18F-FDG-PET/CT on staging of cervical cancer.
|
30769369 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aim of the study was to assess impact of pretherapeutic FDG-PET/CT metabolic parameters on response to chemoradiotherapy (CRT) and survival in locally advanced cervical cancer (LACC) patients without paraaortic lymph node involvement.
|
30729273 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy.
|
31069132 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inclusion of 18F-FDG-PET/CT in the pre-therapy assessment of cervical cancer improves the accuracy of staging in about half of the patients.
|
30998728 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/MRI was superior to FDG PET/CT for the detection of local tumour invasion in cervical cancer and had higher accuracy for the detection of liver metastases in colorectal cancer.
|
31267161 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The maximum and mean SUV of <sup>18</sup>F-FDG PET/CT (SUVmax and SUVmean) and the minimum ADC (ADCmin) were collected from 72 patients with CC.
|
31273350 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We designed a deep learning model for assessing <sup>18</sup>F-FDG PET/CT for early prediction of local and distant failures for patients with locally advanced cervical cancer.
|
31134366 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection.
|
31089075 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Added value of para-aortic surgical staging compared to <sup>18</sup>F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.
|
31784203 |
2019 |
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The [18F] FDG PET-CT imaging data of 394 patients who were newly diagnosed with cervical cancer (FIGO stage, Ia-IIa) were retrospectively studied.
|
30927941 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG-PET/CT guided external beam radiotherapy volumes in inoperable uterine cervical cancer.
|
29869485 |
2018 |
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ADC histogram analysis and volume-based metabolic 18F-FDG-PET parameters are related to each other in cervical cancer.
|
30154687 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive Value of FDG PET/CT to Detect Lymph Node Metastases in Cervical Cancer.
|
30153151 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of posttreatment <sup>18</sup>F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters.
|
30069578 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG PET/CT in the evaluation of cancer cervix: Where do we stand today?
|
29683929 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> A total number of 42 patients who were treated for cervical squamous cell carcinoma and had underwent <sup>18</sup>F-FDG PET/CT for suspected recurrence of cervical cancer were retrospectively reviewed in this study and their clinical, pathological and serological data were collected and analyzed.
|
30210633 |
2018 |
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interim <sup>18</sup>F FDG-PET imaging in rectal and cervical cancer, the main malignancies of the pelvic district, has been applied and a broad literature is available, although some results are discordant.
|
28427517 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners.
|
28574816 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is a case report of a cutaneous angiosarcoma of the lower anterior abdomen showing increased FDG uptake on F-FDG PET/CT mimicking a cutaneous metastasis in an 84-year-old woman with cervical cancer.
|
28632698 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A high F-FDG uptake was found in a mesh of promontofixation in a 74-year-old woman who underwent a PET/CT scan for initial staging of cervical cancer.
|
27819855 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer.
|
28423698 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the prognostic value for predicting tumor recurrence of intratumoral metabolic heterogeneity and traditional quantitative metabolic parameters on pre-treatment F-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT).
|
29163839 |
2017 |